NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 137 filers reported holding NEKTAR THERAPEUTICS in Q3 2023. The put-call ratio across all filers is 5.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6 | +50.0% | 10,625 | +49.4% | 0.00% | – |
| Q2 2023 | $4 | +33.3% | 7,110 | +43.3% | 0.00% | – |
| Q1 2023 | $3 | -76.9% | 4,961 | -19.0% | 0.00% | – |
| Q4 2022 | $13 | -100.0% | 6,123 | -68.3% | 0.00% | – |
| Q3 2022 | $61,000 | +10.9% | 19,304 | +31.4% | 0.00% | – |
| Q2 2022 | $55,000 | -45.5% | 14,696 | -22.2% | 0.00% | – |
| Q1 2022 | $101,000 | +1.0% | 18,900 | +229.1% | 0.00% | – |
| Q3 2021 | $100,000 | -10.7% | 5,743 | -12.2% | 0.00% | – |
| Q2 2021 | $112,000 | -1.8% | 6,543 | +14.6% | 0.00% | – |
| Q1 2021 | $114,000 | +34.1% | 5,707 | +13.0% | 0.00% | – |
| Q4 2020 | $85,000 | -81.7% | 5,050 | -82.0% | 0.00% | -100.0% |
| Q3 2020 | $464,000 | -34.3% | 28,016 | -8.2% | 0.00% | 0.0% |
| Q2 2020 | $706,000 | +5.1% | 30,520 | -19.0% | 0.00% | 0.0% |
| Q1 2020 | $672,000 | -61.6% | 37,667 | -53.5% | 0.00% | -75.0% |
| Q4 2019 | $1,748,000 | +96.8% | 80,984 | +66.1% | 0.00% | +33.3% |
| Q3 2019 | $888,000 | +166.7% | 48,752 | +420.4% | 0.00% | +200.0% |
| Q2 2019 | $333,000 | -57.2% | 9,369 | -59.6% | 0.00% | -50.0% |
| Q1 2019 | $778,000 | +75.6% | 23,171 | +71.9% | 0.00% | +100.0% |
| Q4 2018 | $443,000 | -75.3% | 13,479 | -54.2% | 0.00% | -83.3% |
| Q3 2018 | $1,795,000 | +11.8% | 29,446 | -10.5% | 0.01% | 0.0% |
| Q2 2018 | $1,605,000 | -14.9% | 32,887 | +85.2% | 0.01% | -92.8% |
| Q1 2018 | $1,887,000 | +154.0% | 17,759 | -42.6% | 0.08% | +176.7% |
| Q3 2017 | $743,000 | +1060.9% | 30,964 | +832.7% | 0.03% | +900.0% |
| Q2 2017 | $64,000 | +481.8% | 3,320 | +564.0% | 0.00% | – |
| Q1 2017 | $11,000 | -96.2% | 500 | -97.9% | 0.00% | -100.0% |
| Q4 2016 | $286,000 | +521.7% | 23,312 | +755.2% | 0.02% | +466.7% |
| Q3 2016 | $46,000 | +228.6% | 2,726 | +162.1% | 0.00% | +200.0% |
| Q2 2016 | $14,000 | -26.3% | 1,040 | -27.5% | 0.00% | -50.0% |
| Q1 2016 | $19,000 | -86.4% | 1,435 | -88.8% | 0.00% | -80.0% |
| Q3 2015 | $140,000 | +129.5% | 12,780 | +128.3% | 0.01% | +42.9% |
| Q1 2015 | $61,000 | -68.2% | 5,599 | -54.9% | 0.01% | -69.6% |
| Q4 2014 | $192,000 | – | 12,414 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |